Journal
PHARMACEUTICALS
Volume 14, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/ph14101053
Keywords
mucin; MUC1; MUC16; immunotherapy; cancer vaccine; CAR (chimeric antigen receptor); ADC (antibody-drug conjugate)
Categories
Funding
- National Research Foundation of Korea [NRF-2020R1A4A1016695]
- KIST institutional program
Ask authors/readers for more resources
The MUC family is highly glycosylated macromolecules abundantly expressed in mammalian epithelial cells, contributing to the mucus barrier formation against infection. Some MUC proteins are aberrantly expressed in cancer cells, involved in cancer development and progression, regarded as promising therapeutic targets and biomarkers.
The mucin (MUC) family is a group of highly glycosylated macromolecules that are abundantly expressed in mammalian epithelial cells. MUC proteins contribute to the formation of the mucus barrier and thus have protective functions against infection. Interestingly, some MUC proteins are aberrantly expressed in cancer cells and are involved in cancer development and progression, including cell growth, proliferation, the inhibition of apoptosis, chemoresistance, metabolic reprogramming, and immune evasion. With their unique biological and structural features, MUC proteins have been considered promising therapeutic targets and also biomarkers for human cancer. In this review, we discuss the biological roles of the transmembrane mucins MUC1 and MUC16 in the context of hallmarks of cancer and current efforts to develop MUC1- and MUC16-targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available